CD Genomics Supercharges Transcriptomics Research by Digital RNA Sequencing Technology

uMotif – the patient-first data capture and decentralized clinical trials platform – announces $25.5m of new investment from a fund managed by Athyrium Capital Management

uMotif – the patient-first data capture and decentralized clinical trials platform – announces $25.5m of new investment from a fund managed by Athyrium Capital Management LONDON and NEW YORK, May 25, 2022-- uMotif today announced a new investment of $25.5m from a fund managed by Athyrium Capital Management, LP, the New York-based investment firm. The new funding will support continued scale up of uMotif's unique patient-first software platform for clinical research.

CD BioSciences Introduces Comprehensive Solutions for GPCR Expression

CD BioSciences introduces comprehensive solutions for GPCR expression based on various strategies and technique platforms to facilitate customers’ cutting-edge programs.

STEMart Introduces Biocompatibility Evaluation of Breathing Gas Pathways in Medical Devices

STEMart expands its Biocompatibility Testing services and introduces biocompatibility evaluation of breathing gas pathways in medical devices.

Amerigo Scientific Supports Microbiology Research with the Launch of HHD BROTH

Amerigo Scientific now introduces HHD Broth to the life science research community.

Creative Diagnostics Launches Antibody-dependent Enhancement Assay Services

Creative Diagnostics recently introduces comprehensive services for antibody-dependent enhancement (ADE) assay.

New Research Shows More Americans Avoiding Healthcare Due to Uncertainty About Costs

HealthSparq Annual Consumer Survey Reveals Strong Support for Price Transparency Government Mandates

Thermo Fisher Scientific and Qatar Genome Program Partner to Advance Precision Medicine

MMS Holdings Selects THREAD as Partner of Choice to Deliver Decentralized Clinical Trials

MMS Holdings Inc. (MMS) – a data-focused contract research organization (CRO) – announced a collaboration with THREAD® as its partner of choice for its decentralized clinical trial platform (DCT) and DCT-enabled services, solidifying MMS as a full-service DCT provider. The THREAD partnership is one initiative of many at MMS dedicated to accelerating a path toward adopting more patient-focused clinical trials

New study highlights talent needed to grow the biosimilars sector

The RSA Group, a leading life sciences executive search firm, has published the latest of its Talent Equity® Reports: Biosimilars 2022. The new report features interviews with leaders of biosimilars companies who give their unique insights into the challenges and opportunities facing this fast-growing sector and the leadership needed to grow the industry, including the power of creating strong in-house knowledge and evaluating where this talent already exists.

Creative Proteomics Cytokine Unveils Tumor Necrosis Factors (TNF) Detection Service

Creative Proteomics Lipidomics Platform Boosts Short Chain Fatty Acids Research

Pronalyse Unveils Therapeutic Enzyme Characterization Service for Your Drug Development

Qlucore adds another cancer diagnostics area

Qlucore, listed on Nasdaq First North, is delighted to announce a new collaboration in the field of precision diagnostics to develop solutions for improved clinical diagnostics of bladder cancer. Bladder cancer is the third classifier model co-operation launched by Qlucore in the area of solid tumours.

mdgroup Growth sees New VP, Product Delivery, Investing for the Future

mdgroup Growth sees New VP, Product Delivery, Investing for the Future Bracknell, UK: 19 May 2022 – mdgroup, the leading global provider of healthcare technologies and personalised clinical study services, has charged its new VP, Product Delivery, Mohamad (Mo) Merhi, with doubling the development team and recruiting the highest calibre of global talent in technological development and innovation.

BioMoti collaborates with global pharmaceutical company to develop ovarian cancer treatment and appoints Dr John Beadle as Chairman

BioMoti Ltd today announces an agreement with a global pharmaceutical company to collaborate on the development of its lead ovarian cancer candidate, BMT101, to clinical phase 2a proof-of-concept.

FDA grants 510k clearance of the CTL Amedica Navigation Instrument System

CTL Amedica Corporation has received official 510k clearance from the U.S. FDA to market the CTL Amedica Navigation Instrument System, registration number K213491. The system features manual surgical instruments adaptable for use with third-party navigation systems, which are designed to assist surgeons in precisely locating anatomical structures for preparation and placement of pedicle screws.

ZeOmega Unveils Novel Electronic Prior Authorization Solution

Through Partnerships with Change Healthcare and MCG, ZeOmega’s HealthUnity™ Smart Authorization Gateway Saves Time, Lowers Costs and Reduces Delays in Patient Care

BOC Sciences Officially Releases the Final Invitation to Renowned Pharma Conferences in May

As the two industry-renowned exhibitions—CPhI North America and TIDES USA 2022 draw near, BOC Sciences is making final efforts to let the news reach as many researchers as possible, especially those who are struggling to find the best mRNA services.

Carbohydrates of BOC Sciences Reveal Myriad Possibilities for Therapeutics

BOC Sciences updated several carbohydrates and derivatives in July 2020 and has kept a constant enlargement of product categories since then. Currently, it provides a full spectrum of carbohydrates that dramatically boost the research in Glycochemistry, Glycobiology, Glyco-analytics, and other Glycosciences.